SIG
AZN icon

Stanford Investment Group’s AstraZeneca AZN Stock Holding History

Stanford Investment Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13
Closed -$1K – 21
2016
Q4 		$1K Hold
13
– – ﹤0.01% 364
2016
Q3 		$1K Buy
+13
New +$850 ﹤0.01% 402

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Stanford Investment Group's AZN Position: Q1 2017 in Review

Stanford Investment Group sold out of AstraZeneca (AZN) in Q1 2017, closing a stake of 13 shares — an estimated $1K sold.

Stanford Investment Group first reported a position in AZN in Q3 2016 and held it in 2 quarters. The position peaked at $1K in Q4 2016. 461 funds tracked by Wall St. Rank hold AZN as of Q1 2017.

  • Stanford Investment Group reported no remaining AstraZeneca position as of Q1 2017 after selling out during the quarter.
  • Stanford Investment Group sold 13 AstraZeneca shares in Q1 2017, an estimated $1K.
  • Stanford Investment Group first reported a position in AstraZeneca in Q3 2016 and held it in 2 quarters.
  • Stanford Investment Group's AstraZeneca position peaked at $1K in Q4 2016.
  • 461 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2017.

Based on Stanford Investment Group's 13F filing for Q1 2017.